Health Trials

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

ConditionsUrothelial CarcinomaUrothelial Carcinoma RecurrentUrothelial Carcinoma UreterUrothelial Carcinoma Ureter RecurrentUrothelial Cancer of Renal PelvisUrothelial Carcinoma of the Renal Pelvis and UreterCarcinoma, Transitional CellTransitional Cell Carcinoma of Renal Pelvis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUroGen Pharma Ltd.

About this trial

The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.

Eligibility criteria

Qualifiers

Adults >18 years old and capable of giving informed consent.

Diagnosis of UTUC.

Receipt of at least 1 dose of JELMYTO after FDA approval (15 Apr 2020).

Disqualifiers

Incapable of giving informed consent (e.g., incarcerated individuals, individuals with dementia).

Receipt of 1 or more doses of JELMYTO (also referred to as UGN-101 or Mitogel in clinical development) before FDA approval (on or before 15 Apr 2020).

Pregnancy or lactation.

Unable to comply with protocol requirements (for prospective data capture).

Trial design

Treatments tested in this trial

  • Jelmyto (mitomycin) for pyelocalyceal solution

Treatment groups

400 Participants
are divided into 1 treatment group

Sponsors and collaborators

UroGen Pharma Ltd.

Lead sponsor

Source ClinicalTrials.gov